Gemtesa / Obgemsa  (generic name: vibegron) is an FDA-approved medication prescribed for the treatment of overactive bladder (OAB) in adults, including those on pharmacological therapy for benign prostatic hyperplasia (BPH). It addresses symptoms such as urge urinary incontinence, urgency, and urinary frequency.
Vibegron, the active ingredient in Gemtesa, is a beta-3 adrenergic agonist. It works by selectively stimulating beta-3 adrenergic receptors in the bladder’s detrusor muscle, leading to muscle relaxation. This relaxation increases bladder capacity and reduces involuntary contractions, which can alleviate OAB symptoms.
Clinical studies have demonstrated that Gemtesa significantly reduces the frequency of urination, urgency episodes, and incontinence episodes in patients with OAB. Patients reported improvements in quality of life and a reduction in the disruptive impact of OAB symptoms on daily activities.
Dosage
The standard dosage of Gemtesa is 75 mg, taken orally once daily. The tablet can be taken with or without food.
Swallow the tablet whole with a glass of water. For patients who have difficulty swallowing tablets, Gemtesa can be crushed and mixed with approximately one tablespoon (15 mL) of applesauce, immediately followed by a glass of water.
If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double-dose to make up for a missed dose.
Storage
Store Gemtesa at room temperature, between 68°-77°F (20°-25°C). Keep the medication in its original container to protect it from moisture and light.
Common Questions About Gemtesa
Is vibegron safe for long-term use?
Clinical studies have demonstrated that vibegron is
safe and effective for long-term use in patients with OAB. Long-term data indicate sustained improvements in
urinary urgency, incontinence, and frequency with a
low incidence of side effects.
How does vibegron differ from other OAB treatments?
Vibegron differs from
anticholinergic drugs because it specifically
activates beta-3 adrenergic receptors in the bladder without affecting muscarinic receptors. This selectivity helps reduce OAB symptoms while minimizing common
anticholinergic side effects such as dry mouth and blurred vision.
How effective is Gemtesa for an overactive bladder?
Gemtesa has been shown to
significantly reduce urinary urgency, frequency, and incontinence episodes. In clinical trials, patients taking Gemtesa reported improved bladder control and
fewer nighttime bathroom visits compared to a placebo.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
Read the information leaflet that comes with the medication.
If a sudden allergic reaction (anaphylaxis) occurs after taking Gemtesa, with symptoms like swelling of the face, tongue, or throat making it difficult to breathe or swallow, or there is wheezing, hives, rash, blistering, or peeling of the skin, call a doctor or 911 right away, or go to an emergency room immediately.
Most people who use Gemtesa do not experience any adverse side effects. Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include:
- Headache
- Urinary Tract Infection
- Nasal Congestion
- Sore Throat or Runny Nose
- Diarrhea
- Nausea
- Upper Respiratory Tract Infection
These side effects were reported in clinical trials. They are generally mild and clear up on their own.
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
FDA-approved uses for Gemtesa are :
- Overactive bladder in adults
- To treat adult males taking medicine for benign prostatic hyperplasia (BPH).
Symptoms include:
-
-
Urge Urinary Incontinence: Involuntary leakage of urine following a sudden, intense urge to urinate.
-
Urgency: A compelling need to urinate immediately.
-
Frequency: Needing to urinate more often than usual, typically more than eight times in 24 hours.